1. Pink Sheet

Goodbye Gleevec? Sprycel, Tasigna Vie For Front-Line CML Leadership

 
• By Jessica Merrill

BMS' Sprycel and Novartis' Tasigna perform better on key endpoints than standard of care, Gleevec, in first-line treatment of chronic myeloid leukemia.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Pink Sheet